Abstract
Talquetamab, a bispecific antibody targeting GPRC5D and CD3, has led to durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma in phase 1–2 trials, with a lim...
Cite
CITATION STYLE
APA
Mina, R., Beksac, M., Rodríguez-Otero, P., Chen, W., Mateos, M.-V., Li, J., … Voorhees, P. M. (2026). Talquetamab–Daratumumab in Relapsed or Refractory Myeloma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2604657
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free